Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301150 | 0.85 | ABL1 (0.43) | SRCABL1FGFR1EGFRLCK | |
| SCHEMBL29897393 | 0.82 | ABL1 (0.42) | SRCABL1FGFR1FGFR4LCK | |
| SCHEMBL23301569 | 0.82 | ABL1 (0.42) | SRCABL1FGFR1FGFR4LCK | |
| SCHEMBL29897338 | 0.80 | SRC (0.44) | SRCABL1FGFR1EGFRFGFR2 | |
| SCHEMBL23301167 | 0.80 | SRC (0.44) | SRCABL1FGFR1EGFRFGFR2 | |
| SCHEMBL5494660 | 0.77 | LCK (0.64) | SRCABL1FGFR1FGFR4LCK | |
| SCHEMBL30175753 | 0.74 | ABL1 (0.45) | SRCABL1FGFR1KDRJAK3 | |
| SCHEMBL25044286 | 0.74 | ABL1 (0.45) | SRCABL1FGFR1KDRJAK3 | |
| SCHEMBL25043278 | 0.73 | KDR (0.54) | SRCABL1FGFR1EGFRFGFR2 | |
| SCHEMBL30175742 | 0.73 | KDR (0.54) | SRCABL1FGFR1EGFRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-4051664-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | Cancer Research Technology Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | SRC 334/4885ABL1 407/4885FGFR1 635/4885 |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | SRC 272/4885ABL1 444/4885FGFR1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.